Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk

World Journal of Gastroenterology

Volumn 11, Issue 27, 2005, Pages 4268-4271

  He, Lu Jun ^a   Yu, Yue Ming ^a   Qiao, Fang ^b   Liu, Jing Shan ^b   Sun, Xiao Feng ^c   Jiang, Ling Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Province Blood Center   (China)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Colorectal cancer; NAT2 gene; RFLP

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENOMIC DNA;

ADULT; AGED; ARTICLE; BLOOD CELL; CANCER RISK; CANCER TISSUE; CASE CONTROL STUDY; CHINESE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL SERVICE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; WILD TYPE;

EID: 23144434763     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i27.4268     Document Type: Article

References (13)

1. Pande JN, Pande A, Singh SP. Acetylator status, drug metabolism and disease. Natl Med J India 2003; 16: 24-26
2. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutant Res 2002; 30: 65-77
3. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 29-42
4. Rodriguez JW, Kirlin WG, Ferguson RJ, Doll MA, Gray K, Rustan TD, Lee ME, Kemp K, Urso P, Hein DW. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993; 67: 445-452
5. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf CR. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002; 23: 1839-1849
6. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phentype discordance for human arylamine N-acetyltransferase(NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692
7. Lee EJ, Zhao B, Seow-Choen F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. Pharmacogenetics 1998; 8: 513-517
8. Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11: 207-215
9. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79
10. Evans DA. N-acetyltransferase. Pharmacol Ther 1989; 42: 157-234
11. Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000; 56: 689-692
12. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, Augustsson K, Wolf CR, Bishop DT, Forman D. Colorectal Cancer Stusy Group. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 2003; 24: 275-282
13. Schnakenberg E, Ehlers C, Feyerabend W, Werdin R, Hubotter R, Dreikorn K, Schloot W. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin Genet 1998; 53: 396-402